More Timely Care for Chronic Liver Disease is Coming, Step-by-Step, says Hepatologist Bruce Luxon, MD, PhD
Reducing stigma associated with chronic liver disease and expediting diagnosis and referral will take some time but progress is being made, Luxon says.
To Help Reduce the Burden of Chronic Liver Disease, Primary Care Needs Simple, Reliable, Available Tools
Transplant hepatologist Dr Bruce Luxon says primary care is essential to making progress against chronic liver disease but doesn't have the resources it needs.
10 Top Studies from The Liver Meeting 2023: At-a-Glance
Simplified risk stratification tools for NAFLD, effects of statins on hepatic disease, trends in OHE, and patient perspectives are samples of the noteworthy research areas.
Underestimation of OHE Hospitalizations: Author of New Study Discusses Clinical Implications, Takeaways for Primary Care Clinicians
Arun Jesudian, MD, details key findings from a study he recently presented at The Liver Meeting 2023.
Speech May be a Promising Biomarker for MHE, OHE, According to New Research
TLM 2023: Speech analyzed from a smartphone app recording identified MHE and predicted OHE with results comparable to those from validated assessments.
How to Change the Course of Chronic Liver Disease in the US: Create a Groundswell Movement
TLM 2023: Reduce disease stigma and treatment inequality, build awareness for early diagnosis across specialties, support clinicians with accessible tools, and that's a start.
NASH Diagnosis: Patients Overwhelmed But Motivated to Adhere to Guidance and Want More Help, Survey Finds
More education that is clear and from reliable sources is needed for patients with a NASH diagnosis and their caregivers throughout the duration of the disease.
Cloud-Based "Liver Toolkit" Identifies Primary Care Patients at High Risk for Fibrosis, Requiring Referral
One in 5 patients identified as at risk for advanced chronic liver disease had advanced fibrosis and PCP was prompted to refer to hepatology.
FIB-4 Risk-Stratification Algorithm for MASLD Improved Primary Care Practice Patterns, According to New Research
TLM 2023: Primary care clinicians exposed to a FIB4-based risk stratification algorithm reported applying it routinely for patients with elevated LFTs after the introduction.
New Data Show Rise in Decompensated Cirrhosis and Hepatic Encephalopathy Cases among US Medicare Beneficiaries
TLM 2023: Over 15 years, decompensated cirrhosis and OHE notably rose among Medicare beneficiaries with cirrhosis, exceeding 40% and 20% in 2020.
New NAFLD Familial Risk Score Outperforms FIB-4 for Predicting Advanced Fibrosis in First-Degree Relatives
TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.
Novel Algorithm, FAST-3, Shows Promise as Noninvasive Classifier for Advanced Fibrosis in MASLD
The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.
Hepatic Steatosis is a Risk Factor for MACE, Even Among Individuals at Low 10-Year ASCVD Risk
TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.
Rifaximin Significantly Reduced Recurrent OHE and Associated Health Care Utilization
TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.
Statin Protection Against Cirrhosis in Adults with NAFLD More Pronounced with Age
TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.
New Research Reveals Underestimation of Overt Hepatic Encephalopathy Hospitalizations in US
TLM 2023: Relying solely on a primary diagnosis for overt hepatic encephalopathy underestimates the actual rate, length of stay, and costs of OHE hospitalizations.
STUDY: Novel “Triagonist” Retatrutide Resolved Steatosis in Over 85% of Patients with MASLD and Obesity
TLM 2023: In participants with metabolic dysfunction-associated steatotic liver disease, retatrutide 8 mg and 12 mg resolved steatosis in >85% of subjects.
It's High Time to Retire NAFLD: Multinational Liver Societies Explain
NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.
NAFLD is Now MASLD: The New Nomenclature, At-a-Glance
The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.
The Liver Meeting 2023: AASLD Offers "Journey Maps" to Focused Areas of Interest
We took The Liver Meeting's 11 journey maps to educational sessions and focused on 4 that will be of interest to primary care.
